Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus (RUBY)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
DIAMOND System
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring DIAMOND System, T2DM, Randomized study, Electrical stimulation, Fundus
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects 21 through 70 years of age
- Body mass index ≥28 and ≤ 45 (kg/m2)
- Type 2 diabetes duration more than 6 months and less than 10 years.
- A baseline measurement (visit BL1) of HbA1c between ≥ 7.5% and ≤ 10.5%,
- Type 2 diabetic subjects treated for at least 3 months with one or more maximum tolerable dosage of anti-diabetic agent (Any of the following: Sulfonylurea, Metformin, thiazolinedione (TZD), DPP-4 inhibitors).
- Stable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment, if taken
- Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
- Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the System
- Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
- Able to provide voluntary informed consent
Exclusion Criteria:
- Injectable anti-diabetic therapy within the last 3 months (such as insulin and/or GLP-1 receptor agonists)
- Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics
- Any gastric or upper GI surgery
- Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)
- Prior wound healing problems
- Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures
- Use of anti-psychotic medications
- Diagnosed with an eating disorder such as bulimia or binge eating
- Obesity due to an endocrinopathy (e.g. Cushing disease, Hypothyroidism not treated)
- Hiatal hernia requiring surgical repair or a paraesophageal hernia
- Pregnant or lactating
- Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)
- Any prior bariatric surgery
- Any history of pancreatitis
- Any history of peptic ulcer disease within 10 years of enrollment
- Diagnosed with Gastroparesis or other GI motility disorder
- Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.
- Cardiac history that physician /surgeon feels should exclude the subject from the study.
- Use of another investigational device or agent in the 30 days prior to enrollment
- A history of life-threatening disease within 5 years of enrollment
- Any additional condition(s) that in the Investigator"s opinion would warrant exclusion from the study or prevent the subject from completing the study
Sites / Locations
- Hospital Georges Pompidou
- Atrium Medisch Centrum
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Electrical signal ON
Sham
Arm Description
Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
Subjects randomized to this group (Group B) will have their device in "turned off" mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study.
Outcomes
Primary Outcome Measures
HbA1c
The primary end point will be the difference, at 12 months, in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.
Secondary Outcome Measures
HbA1c
The difference, at 6 months in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.
GI hormones (C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin)
To detect differences in the pattern of meal-related release of GI hormones (slope / area under the curve, etc)between the treatment and the control groups, as analyzed by repeated-measures ANOVA. Glucose, insulin and the following GI hormones will be measured prior and post meal consumption: C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin.
Metabolic parameters (fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference)
The difference in metabolic parameters at 6 and 12 months from baseline between the two arms. Including: fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference.
Triglycerides
The effect of the TG level at baseline on treatment efficacy
HbA1c
The change in HbA1c from baseline to 12 months and 24 months
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01529216
Brief Title
Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus
Acronym
RUBY
Official Title
An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MetaCure Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study purpose is to demonstrate the benefit of a simplified version of the DIAMOND System (A third Generation) in comparison to a sham treatment in terms of Glycemic control, measured as A1c, FBG and Post-Prandial Glucose levels.
The study hypothesis is that HbA1c will show greater improvement in patients receiving 12 months of therapy by the DIAMOMD System than in patients not receiving this therapy.
Detailed Description
The study protocol will also apply measures to better understand the mechanism of action of the effect.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
DIAMOND System, T2DM, Randomized study, Electrical stimulation, Fundus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
2 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Electrical signal ON
Arm Type
Experimental
Arm Description
Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
Subjects randomized to this group (Group B) will have their device in "turned off" mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study.
Intervention Type
Device
Intervention Name(s)
DIAMOND System
Intervention Description
Electrical stimulation to the fundus
Primary Outcome Measure Information:
Title
HbA1c
Description
The primary end point will be the difference, at 12 months, in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
HbA1c
Description
The difference, at 6 months in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.
Time Frame
6 months
Title
GI hormones (C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin)
Description
To detect differences in the pattern of meal-related release of GI hormones (slope / area under the curve, etc)between the treatment and the control groups, as analyzed by repeated-measures ANOVA. Glucose, insulin and the following GI hormones will be measured prior and post meal consumption: C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin.
Time Frame
6 and 12 months
Title
Metabolic parameters (fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference)
Description
The difference in metabolic parameters at 6 and 12 months from baseline between the two arms. Including: fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference.
Time Frame
6 and 12 months
Title
Triglycerides
Description
The effect of the TG level at baseline on treatment efficacy
Time Frame
Baseline
Title
HbA1c
Description
The change in HbA1c from baseline to 12 months and 24 months
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female subjects 21 through 70 years of age
Body mass index ≥28 and ≤ 45 (kg/m2)
Type 2 diabetes duration more than 6 months and less than 10 years.
A baseline measurement (visit BL1) of HbA1c between ≥ 7.5% and ≤ 10.5%,
Type 2 diabetic subjects treated for at least 3 months with one or more maximum tolerable dosage of anti-diabetic agent (Any of the following: Sulfonylurea, Metformin, thiazolinedione (TZD), DPP-4 inhibitors).
Stable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment, if taken
Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the System
Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
Able to provide voluntary informed consent
Exclusion Criteria:
Injectable anti-diabetic therapy within the last 3 months (such as insulin and/or GLP-1 receptor agonists)
Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics
Any gastric or upper GI surgery
Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)
Prior wound healing problems
Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures
Use of anti-psychotic medications
Diagnosed with an eating disorder such as bulimia or binge eating
Obesity due to an endocrinopathy (e.g. Cushing disease, Hypothyroidism not treated)
Hiatal hernia requiring surgical repair or a paraesophageal hernia
Pregnant or lactating
Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)
Any prior bariatric surgery
Any history of pancreatitis
Any history of peptic ulcer disease within 10 years of enrollment
Diagnosed with Gastroparesis or other GI motility disorder
Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.
Cardiac history that physician /surgeon feels should exclude the subject from the study.
Use of another investigational device or agent in the 30 days prior to enrollment
A history of life-threatening disease within 5 years of enrollment
Any additional condition(s) that in the Investigator"s opinion would warrant exclusion from the study or prevent the subject from completing the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan W.M. Greve, MD
Organizational Affiliation
Atrium medisch centrum METC, Heerlen, The Netherlands
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chevallier, MD
Organizational Affiliation
Hôpital GEORGES POMPIDOU 20 Rue Leblanc 75015 Paris, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Georges Pompidou
City
Paris
Country
France
Facility Name
Atrium Medisch Centrum
City
Heerlen
Country
Netherlands
12. IPD Sharing Statement
Links:
URL
http://www.metacure.com
Description
MetaCure
Learn more about this trial
Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs